My favourite UK share on the entire LSE has fallen 5% in a week! Time to buy?

Harvey Jones has waited for years to buy this brilliant UK share. Has the recent stock market dip finally handed him an opportunity to do so?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The recent FTSE 100 dip has knocked what I think could be the best UK share of the lot, pharmaceutical giant AstraZeneca (LSE: AZN)? Is this my chance to buy it at a rare discount?

As a rule, I fight shy of super soaraway stocks like this one. Sod’s law suggests they’ll crash as soon as I clamber on board. So I’ve shunned AstraZeneca for years, only to watch its share price grow and grow.

Should you invest £1,000 in Lloyds Banking Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Lloyds Banking Group made the list?

See the 6 stocks

There’s a lot of controversy over CEO salaries, but Astra’s Pascal Soriot has more than justified his by doing a brilliant job since joining in October 2012.

At the start of his tenure, the AstraZeneca share price stood at 2,877p. It peaked at 13,274p a few days before the recent bout of volatility. That’s a rise of 360%. All dividends are on top.

Can it keep climbing like this?

AstraZeneca is comfortably the UK’s biggest company, with a market cap of around £195bn. Oil giant Shell is a distant second at just £157bn. I just wish more LSE-listed businesses could scale up like this one.

The momentum has largely continued with the shares up 16.41% in the last 12 months, although they’re down 5.5% over the week. This doesn’t exactly make them cheap though. AstraZeneca still trades at a whopping 43.03 times earnings. That’s way above the FTSE 100 average of around 15 times.

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Can I justify buying at that price? AstraZeneca continues to bomb along, with first-half revenue up 18% to $25.6bn. It also upgraded full-year 2024 guidance, forecasting mid-teens percentage growth in total revenue and core earnings per share.

All the hard work Soriot has put into building the company’s drugs pipeline is paying off with interest. And with the world getting older and sicker, that’s likely to continue. AstraZeneca also enjoys healthy 82% margins on core product sales.

It’s a top FTSE 100 income growth stock

There will always be risks to investing in pharmaceutical stocks. Getting drugs to market is a tortuous process, with potential failure at every stage.

Successful blockbuster treatments eventually come off patent, hitting revenues. Plus there’s the constant risk of litigation, particularly in the US, which can trigger legal claims for hundreds of millions of dollars. That can hammer share prices. As I’ve discovered through my holding in FTSE 100 rival GSK.

AstraZeneca’s dividend yield is relatively low at 1.53%, but that’s mostly down to the rocketing share price. Dividend per share growth has been a little bumpy, but the general direction is upwards, as this table shows.


Chart by TradingView

This is clearly a brilliant company. My problem is that wiser investors than me discovered this yonks ago, and have reaped the rewards.

Despite the recent dip, I won’t be buying. My GSK shares are trading at just 10.57 times earnings while yielding 3.54%. I’ll sit tight, cross my fingers and hope they catch up with AstraZeneca.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Lloyds Banking Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Lloyds Banking Group made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Pound coins for sale — 51 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

2 cheap FTSE 100 and FTSE 250 growth stocks to consider as stock markets sink

I think these Footsie and FTSE 250 growth shares could be very shrewd buys to consider in the current climate.…

Read more »

Investing Articles

3 shares I’ve bought in the 2025 stock market sell-off

The stock market has experienced a lot of turbulence in recent weeks. Edward Sheldon has been taking advantage and buying…

Read more »

Investing Articles

Investors considering HSBC shares could aim for £8,453 a year in passive income from just £5 a day!

A relatively small daily investment in HSBC shares over several years can produce an extraordinary level of annual passive income…

Read more »

Investing Articles

The Rolls-Royce share price has fallen! Is this the moment investors have been waiting for?

Even the Rolls-Royce share price can't escape current stock market volatility, falling slightly over the last week. Should investors consider…

Read more »

Modern suburban family houses with car on driveway
Investing Articles

Down 59% from its 12-month highs, is this FTSE 250 stock too cheap to ignore?

Shares in FTSE 250 housebuilder Vistry are almost certainly too cheap to ignore. But are they discounted enough to offset…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

As the S&P 500 struggles to recover, here’s what Warren Buffett’s doing

The S&P 500 is fighting to regain its February highs amid ongoing trade tariff uncertainty. Our writer looks to the…

Read more »

Investing Articles

When will Lloyds shares hit £1?

Lloyds shares have surged over the past 12 months, but where will they go next? Dr James Fox thinks there’s…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Stock-market crash: the meltdown of the Magnificent 7

Just before Christmas, these Magnificent Seven stocks were riding high. But after the worst quarter for US stocks since autumn…

Read more »